跳至主要内容
临床试验/NCT03415386
NCT03415386Unknown4 期

A Multi-center Study on the Optimized Antithrombotic Therapy of Acute Myocardial Infarction With Left Ventricular Mural Thrombus.

The First Affiliated Hospital with Nanjing Medical University0 个研究点目标入组 120 人开始时间: 2020年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
120
主要终点
Left ventricular mural thrombus-1

研究概览

简要总结

A multi-center study will be done to explore the optimal regimen of antithrombotic therapy for acute myocardial infarction with left ventricular mural thrombus. The investigators will evaluate the different combinations of antiplatelet drugs and anticoagulants for at least one month, such as aspirin 100mg qd+clopidogrel 75mg qd+warfarin (INR1.8-2.2), aspirin 100mg qd+clopidogrel 75mg qd+dabigatran 110mg bid, aspirin 100mg qd+ticagrelor 60mg bid+warfarin (INR1.8-2.2), and aspirin 100mg qd+ticagrelor 60mg bid+dabigatran 110mg bid. Transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel 75mg qd/ticagrelor 60mg bid. Then the investigators will complete the 12-month follow-up to evaluate the efficacy and safety of the optimal antithrombotic therapy regimen for acute myocardial infarction with left ventricular mural thrombus.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Sequential
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
20 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • acute myocardial infarction with left ventricular mural thrombus

排除标准

  • BARC bleedings ≥ 2
  • atrial fibrillation
  • acute stroke or other systemic circulation embolism

研究组 & 干预措施

aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2)

Experimental

干预措施: Combination of antiplatelet drugs and anticoagulants for at least one month (Drug)

aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid

Experimental

干预措施: Combination of antiplatelet drugs and anticoagulants for at least one month (Drug)

aspirin100mg qd+ticagrelor60mg bid+warfarin(INR1.8-2.2)

Experimental

干预措施: Combination of antiplatelet drugs and anticoagulants for at least one month (Drug)

aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid

Experimental

干预措施: Combination of antiplatelet drugs and anticoagulants for at least one month (Drug)

结局指标

主要结局

Left ventricular mural thrombus-1

时间窗: 1-month

Number of Participants Without left ventricular mural thrombus as Assessed by echocardiograph at 1-month.

Left ventricular mural thrombus-3

时间窗: 3-month

Number of Participants Without left ventricular mural thrombus as Assessed by echocardiograph at 3-month.

Left ventricular mural thrombus-6

时间窗: 6-month

Number of Participants Without left ventricular mural thrombus as Assessed by echocardiograph at 6-month.

次要结局

  • Target vessel revascularization(12 months)
  • Major cardio-cerebral vascular events(12 months)
  • Recurrent myocardial infarction(12 months)
  • Stent restenosis(12 months)
  • Death(12 months)
  • Stroke or other systemic circulation embolism(12 months)

研究者

申办方类型
Other
责任方
Sponsor

相似试验